JPH0971523A - Tablet quickly disintegrating in oral cavity - Google Patents

Tablet quickly disintegrating in oral cavity

Info

Publication number
JPH0971523A
JPH0971523A JP26458395A JP26458395A JPH0971523A JP H0971523 A JPH0971523 A JP H0971523A JP 26458395 A JP26458395 A JP 26458395A JP 26458395 A JP26458395 A JP 26458395A JP H0971523 A JPH0971523 A JP H0971523A
Authority
JP
Grant status
Application
Patent type
Prior art keywords
tablet
low
oral cavity
crystalline cellulose
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP26458395A
Other languages
Japanese (ja)
Inventor
Miyuki Kiriyama
Keiichi Koizumi
Mitsuo Matsumoto
Yoshiteru Watanabe
Yoshiko Zama
桂一 小泉
喜子 座間
光雄 松本
美由紀 桐山
善照 渡辺
Original Assignee
Riyuukakusan:Kk
株式会社龍角散
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Abstract

PROBLEM TO BE SOLVED: To obtain a tablet quickly disintegrating in the oral cavity with saliva (or a small amount of water) within about several tens seconds to enable the taking of the tablet by an aged man lacking chewing power or at a place free from available water. SOLUTION: This tablet quickly disintegrating in the oral cavity with saliva (or a small amount of water) (quickly disintegrating tablet) is composed of a composition produced by mixing a hydroxypropyl cellulose having low degree of substitution as a disintegrant, a crystalline cellulose as a diluent and a lubricant. The compounding ratio of the low-substitution degree hydroxyproply cellulose to the crystalline cellulose is 1:(2.3-9).

Description

【発明の詳細な説明】 DETAILED DESCRIPTION OF THE INVENTION

【0001】 [0001]

【発明の属する技術分野】本発明は、口腔内の唾液又は少量の水により噛まずにただちに崩壊してそのまま又は水にて服用できる口腔内において崩壊性の速い錠剤(以下、速崩壊性錠剤という)の組成物および製法を提供する技術分野に関する。 The present invention relates to the fast tablet disintegration property in the oral cavity that can be taken by it or water immediately disintegrate without chewing by saliva or a small amount of water in the oral cavity (hereinafter, referred to rapidly disintegrating tablets compositions), and to the art to provide a method.

【0002】 [0002]

【従来の技術】水無しで服用できる製剤としてはチュアブル錠が、胃腸薬などとして市販されている。 As a formulation that can be taken in the Background of the Invention without water chewable tablets, it is commercially available as such as gastrointestinal drugs. これは服用時に水などの飲料を不要とし、必要なときにすぐに口腔内で噛み砕いて服用できるというものである。 This is that the beverages such as water and unnecessary, can be taken by chewing immediately in the oral cavity when needed at the time of taking. また錠剤型で口腔内で噛まずに速やかに崩壊して、錠剤の嚥下を容易にする製剤は見当たらない。 Further by rapidly disintegrate without chewing in the oral cavity in tablet formulation to facilitate the swallowing of the tablets missing.

【発明が解決しようとする課題】 [Problems that the Invention is to Solve

【0003】上述のチュアブル錠を服用する時に噛み砕くことを必要とすることは、老人などの歯の弱い人たちにとっては、不便である。 [0003] is that it requires that the crunch when you take the above chewable tablets, for the weak people of teeth, such as the elderly, which is inconvenient. また嚥下力の弱い患者にとって口腔内で速やかに崩壊して服用できる錠剤は有用である。 The tablets can be taken rapidly disintegrate in the oral cavity for weak swallowing force the patient is useful.

【0004】本発明は、かかる観点からなされたものであり、口腔内で唾液又は少量の水により数十秒程度で速やかに崩壊して嚥下を容易にする錠剤を提供することを課題とする。 [0004] The present invention has been made from this point of view, it is an object to provide a tablet that facilitates swallowing by rapidly disintegrated in several tens of seconds by the saliva or a small amount of water in the oral cavity.

【0005】本発明の速崩壊性錠剤を必要とする状況としては、水の無い場面での錠剤の服用を必要とする薬剤で、例えば乗り物酔止め薬がある。 [0005] situations requiring fast disintegrating tablet of the present invention is a drug that requires taking tablets with no water scene, for example, a vehicle motion sickness drugs. また、従来の錠剤型では嚥下困難な患者は錠剤を砕いて服用する必要があった。 Further, in the conventional tablet dysphagia patients had to be taken crushed tablets. 本発明の速崩壊性錠剤は口腔内で速く崩壊し、嚥下困難な患者の錠剤の服用に有用である。 Fast disintegrating tablet of the present invention disintegrate fast in the oral cavity, useful in taking tablets dysphagia patients. 特に脳血管障害などで嚥下困難な患者や寝たきりの高齢患者に速崩錠は有用であり、薬物としては高血圧症用薬、脳循環代謝改善薬などがある。 Especially fast disintegrating tablet in dysphagia patients and bedridden elderly patients with cerebrovascular disorders etc are useful, as are drug drugs for hypertension, there is such as cerebral blood flow and metabolism improving drug.

【課題を解決するための手段】 In order to solve the problems]

【0006】本発明者は、上記課題を解決するために、 [0006] The present inventors have found that, in order to solve the above problems,
錠剤の賦形剤および崩壊剤を以下の組成とした。 Excipients and disintegrating agents tablets was following composition.

【0007】すなわち本発明の速崩壊性錠剤は、崩壊剤とする低置換度ヒドロキシプロピルセルロースを1とした時に賦形剤として結晶セルロースを2.3から9の割合の配合比で混合し、滑沢剤を配合・混合し、更に必要があれば着色剤などを配合・混合し打錠することにより錠剤を圧縮成型することを特徴とする。 Namely fast disintegrating tablet of the present invention may be mixed at the mixing ratio of the proportion of crystalline cellulose 2.3 9 as an excipient when the low-substituted hydroxypropylcellulose to disintegrant and 1, smooth the swamp agent compounded and mixed, characterized by compression molding a tablet by tableting by blending and mixing the coloring agent if there is a further need.

【0008】また本発明では速崩壊性錠剤に含有させる薬物としては、乗り物酔いの治療に有効な鎮暈および鎮吐作用を有する薬物である塩酸メクリジンが有用である。 [0008] As a drug to be contained in the rapidly disintegrating tablet in the present invention, meclizine hydrochloride is a drug that has valid vertiginous and antiemetic effects in the treatment of motion sickness are useful. 他に本発明で対象とする乗り物酔いの治療に有効な鎮暈および鎮吐作用を有する薬物としては前述の塩酸メクリジン以外の具体例としては、ジメンヒドリナート、 Specific examples other than the foregoing meclizine hydrochloride as a drug having an effective vertiginous and antiemetic effects in the treatment of motion sickness as an object of the present invention to other, dimenhydrinate,
チエルペラジン、サリチル酸ジフェンヒドラミン+ジプロフィリン、プロメタジンテオクレートなどが挙げられる。 Chieruperajin, salicylic acid diphenhydramine + diprophylline, and the like promethazine Theo crate. 高血圧症用薬としてはカプトプリル、シラザプリル、マレイン酸エナラプリル、リシノプリルなどが挙げられ、脳循環代謝改善薬としてはシンナリジン、ビンポセチン、フマル酸ブロビンカミン、ペントキシフィリン、マレイン酸シネパジド、トラピジル、塩酸ニカルジピン、塩酸フルナリジン、塩酸メクロフェノキサート、 The hypertension for captopril, cilazapril, enalapril maleate, etc. lisinopril. Examples of the cerebral circulation metabolism improving agents cinnarizine, vinpocetine, Burobinkamin fumarate, pentoxifylline, cinepazide maleate, trapidil, nicardipine, hydrochloride Flunarizine , hydrochloric meclofenoxate,
酒石酸イフェンプロジルなどが挙げられる。 Such as tartaric acid ifenprodil and the like.

【0009】以下、本発明を説明する。 [0009] The present invention will now be described.

【0010】<1>本発明の速崩壊性錠剤の製法 1)組成物 本発明では一般的に使用される下記の賦形剤、崩壊剤を使用して速崩壊性錠剤を作ることを特徴としている。 [0010] As a feature to make <1> fast disintegrating tablet production method 1) The following excipients commonly used in Compositions of the Invention The present invention, the rapidly disintegrating tablets using a disintegrating agent there. 結晶セルロース(賦形剤) (旭化成工業(株)製アビセルPH−102、粒子径1 Crystalline cellulose (excipient) (Asahi Chemical Industry Co., Ltd. Avicel PH-102, particle size 1
00μm) 低置換度ヒドロキシプロピルセルロース(崩壊剤) (信越化学工業(株)製L−HPC、粒子径160μ 00Myuemu) Low substituted hydroxypropylcellulose (disintegrant) (Shin-Etsu Chemical Co., Ltd. L-HPC, particle diameter 160μ
m、日本薬局方12局収載) m, the Japanese Pharmacopoeia 12 stations listed)

【0011】2)本発明の速崩壊性錠剤の配合割合 薬物を含有しない速崩壊性錠剤 ・ステアリン酸マグネシウム(滑沢剤:和光純薬工業(株)製MS、粒子径70μm)1%、低置換度ヒドロキシプロピルセルロースと結晶セルロースの配合比を1:2.3から1:9で配合・混合したもの各99%上記混合物を打錠用剤とする。 [0011] 2) fast fast disintegrating tablet Magnesium stearate containing no proportion drug disintegrating tablet of the present invention (lubricants: manufactured by Wako Pure Chemical Industries, Ltd. MS, particle size 70 [mu] m) 1%, low the compounding ratio of the substituted hydroxypropyl cellulose and crystalline cellulose 1: 2.3 to 1: 9 each 99% the mixture obtained by blending and mixing for tableting agent.

【0012】薬物(塩酸メクリジン)含有速崩壊性錠剤 ・塩酸メクリジン(鎮暈・鎮吐剤:日本バルク薬品製、 [0012] The drugs (meclizine hydrochloride) containing rapidly disintegrating tablet, meclizine hydrochloride (vertiginous, antiemetic: Japan bulk chemicals, Ltd.,
分子量481.89、融点217℃(分解))10%、 Molecular weight 481.89, melting point 217 ° C. (decomposition)) 10%
ステアリン酸マグネシウム1%、低置換度ヒドロキシプロピルセルロースと結晶セルロースの配合比を1:4混合したもの89% 上記混合物を打錠用剤とする。 Magnesium stearate 1% The compounding ratio of the crystalline cellulose and low-substituted hydroxypropylcellulose 1: 4 mixed ones 89% the mixture for tableting agent.

【0013】3)本発明の速崩壊性錠剤の打錠条件 下記の条件で、錠剤を製造した。 [0013] 3) at a speed tabletting under the following conditions conditions disintegrating tablet of the present invention, tablets were prepared. 一般に成型荷重をかけるほど錠剤の硬度が上がり、崩壊しにくくなるとされている。 Generally raise the tablet hardness as applying a molding load, which is to become difficult collapse. しかし本発明の速崩壊性錠剤は100〜300k However rapidly disintegrating tablet of the present invention 100~300k
gfの成型荷重(以下、打錠圧という)で、硬度のある速崩壊性錠剤を得ることができた。 gf molding load (hereinafter, referred to as compression force) in, it was possible to obtain fast disintegrating tablets with hardness. 装 置 :N−20E型両圧式粉末打錠機(岡田精工(株)製)杵直径8.0mm、曲率半径10R 錠剤重量:200mg 打錠圧 :100〜300kgf Equipment: N-20E type both pressure powder tableting machine (manufactured by Okada Seiko Co.) punch diameter 8.0 mm, the radius of curvature 10R tablet weight: 200 mg Tableting pressure: 100~300Kgf

【0014】<2>本発明の速崩壊性錠剤の効果を測定するための条件 1)錠剤硬度測定 錠剤はある程度かたさ(以下、硬度と言う)がないと錠剤の原型をとどめず、適正な打錠圧で硬度がありながら速崩壊性の錠剤であることが必須条件である。 [0014] <2> Condition 1 for measuring the effect of the rapidly disintegrating tablet of the present invention) tablet hardness measured Tablets somewhat hardness (hereinafter, referred to as hardness) not kept intact tablets and are not proper hitting is an essential condition that a rapidly disintegrating tablet while remaining hardness in tableting pressure. この為に硬度を測定した。 The hardness was measured in order. 後述する市販品素錠の測定では13〜 13 is a measurement of commercially available plain tablet, which will be described later
15Kgの硬度であった。 15Kg was of hardness. 本発明の速崩壊性の錠剤も同様な硬度を得た。 Rapidly disintegrating tablet of the present invention also give a similar hardness. 半自動硬度計(TS−50N型、岡田精工(株)製) 圧縮破壊に要する応力を測定し、これを硬度(kg)とする。 Semi-automatic hardness tester stress required for (TS-50 N type, Okada Seiko Co., Ltd.) compression failure was measured, which is referred to as hardness (kg).

【0015】2)錠剤の崩壊性 速崩壊性錠剤の崩壊性を下記の代用試験により測定した。 [0015] 2) and the disintegration of disintegrating rapidly disintegrating tablets of the tablet was measured by substituting the following test. 本試験の結果は実際の口腔内での結果と相関性がある。 The results of this study are the results correlated with the actual oral cavity. 本発明の速崩壊性錠剤は実施例で示すようにすべて74秒以内で崩壊した。 Fast disintegrating tablet of the present invention disintegrated within all 74 seconds as shown in the examples. 小型シャーレ中の水に錠剤を全浸または半浸させる。 All immersion or give semi-immersed tablets in water in small petri dish. 口腔内での崩壊は、舌の動きが加わるため、この小型シャーレーに弱い振とうを加えて崩壊時間を測定した。 Disintegration in the oral cavity, since the movement of the tongue is applied to measure the disintegration time by adding a weak shaking in this small petri dish. 振とう器 SA−31型(ヤマトサイエンテフィック社製)振幅距離、4cm 振とう回数:40回/分=1回/1.5秒(最小設定値) Shaker SA-31 type (Yamato Scientific Te Scientific Co.) amplitude distance, 4 cm shaking frequency: 40 times / min = once /1.5 second (minimum setting)

【0016】本発明の速崩壊性錠剤(重量200mg、 The rapidly disintegrating tablet (weight 200mg of the present invention,
直径8mm)とほぼ同じ大きさの市販素錠A(重量20 Commercial diameter 8 mm) and approximately the same size plain tablet A (weight 20
0mg、直径8mm)とB(重量280mg、直径9m 0 mg, diameter 8 mm) and B (weight 280 mg, diameter 9m
mを用いて、上記の条件で試験した結果を表1に示す。 With m, Table 1 shows the results of testing under the above conditions.
これらの市販素錠は速崩壊性錠剤と言えないことは明きらかであり、本発明の速崩壊性錠剤は市販素錠とは大いに異なっている。 These commercially available uncoated tablet is a perforated et al or it can not be said with fast disintegrating tablets, rapidly disintegrating tablets of the present invention greatly differ from the commercially available plain tablet.

【0017】 [0017]

【実施例】以下に本発明の実施例を具体的に説明する。 EXAMPLES specifically described embodiments of the present invention are described below.

【0018】 [0018]

【実施例1】低置換度ヒドロキシプロピルセルロースと結晶セルロースの配合比3:7(低置換度ヒドロキシプロピルセルロースを1とすると1:2.3となる)。 EXAMPLE 1 Low-substituted hydroxypropylcellulose and crystalline cellulose mixing ratio 3: 7 (equal to 1 low-substituted hydroxypropylcellulose becomes 1: 2.3). 成 分 量 結晶セルロース 69.3% 低置換度ヒドロキシプロピルセルロース 29.7% ステアリン酸マグネシウム 1.0% 上記粉末を均一に混合した後、打錠機で圧縮した。 After uniformly mixing the Ingredients Amount Crystalline cellulose 69.3% low-substituted hydroxypropylcellulose 29.7 percent magnesium 1.0% above stearate powder was compressed on a tablet machine. 表2 Table 2
に示したように良好な崩壊時間と打錠圧、硬度の関係を得た。 Good disintegration time and compression force as shown in, to obtain a relationship of hardness.

【0019】 [0019]

【実施例2】低置換度ヒドロキシプロピルセルロースと結晶セルロースの配合比1:3.5 成 分 量 結晶セルロース 77.0% 低置換度ヒドロキシプロピルセルロース 22.0% ステアリン酸マグネシウム 1.0% 上記粉末を均一に混合した後、打錠機で圧縮した。 Example 2 low-substituted hydroxypropylcellulose and compounding ratio of crystalline cellulose 1: 3.5 Ingredients Amount Crystalline cellulose 77.0% low-substituted hydroxypropyl cellulose 22.0% Magnesium stearate 1.0% The above powder They were uniformly mixed and compressed on a tablet machine. 表3 Table 3
に示したように良好な崩壊時間と打錠圧、硬度の関係を得た。 Good disintegration time and compression force as shown in, to obtain a relationship of hardness.

【0020】 [0020]

【実施例3】低置換度ヒドロキシプロピルセルロースと結晶セルロース配合比1:4 成 分 量 結晶セルロース 79.2% 低置換度ヒドロキシプロピルセルロース 19.8% ステアリン酸マグネシウム 1.0% 上記粉末を均一に混合した後、打錠機で圧縮した。 Example 3 and low-substituted hydroxypropyl cellulose crystalline cellulose mixing ratio 1: 4 Ingredients Amount Crystalline cellulose 79.2% low-substituted hydroxypropyl cellulose 19.8% Magnesium 1.0% above stearate powder uniformly after mixing, it was compressed on a tablet machine. 表4 Table 4
に示したように良好な崩壊時間と打錠圧、硬度の関係を得た。 Good disintegration time and compression force as shown in, to obtain a relationship of hardness.

【0021】 [0021]

【実施例4】低置換度ヒドロキシプロピルセルロースと結晶セルロースの配合比1:8 成 分 量 結晶セルロース 88.0% 低置換度ヒドロキシプロピルセルロース 11.0% ステアリン酸マグネシウム 1.0% 上記粉末を均一に混合した後、打錠機で圧縮した。 Example 4 low-substituted hydroxypropylcellulose and crystalline cellulose mixing ratio 1: 8 Ingredients Amount Crystalline cellulose 88.0% low-substituted hydroxypropyl cellulose 11.0% Magnesium 1.0% above stearate powder uniformly after mixing in, it was compressed on a tablet machine. 表5 Table 5
に示したように良好な崩壊時間と打錠圧、硬度の関係を得た。 Good disintegration time and compression force as shown in, to obtain a relationship of hardness.

【0022】 [0022]

【実施例5】低置換度ヒドロキシプロピルセルロースと結晶セルロースの配合比1:9 成 分 量 結晶セルロース 89.1% 低置換度ヒドロキシプロピルセルロース 9.9% ステアリン酸マグネシウム 1.0% 上記粉末を均一に混合した後、打錠機で圧縮した。 Example 5 Low-substituted hydroxypropyl cellulose and crystalline cellulose mixing ratio 1: 9 Ingredients Amount Crystalline cellulose 89.1% low-substituted hydroxypropylcellulose 9.9% Magnesium 1.0% above stearate powder uniformly after mixing in, it was compressed on a tablet machine. 表6 Table 6
に示したように良好な崩壊時間と打錠圧、硬度の関係を得た。 Good disintegration time and compression force as shown in, to obtain a relationship of hardness.

【0023】 [0023]

【実施例6】 塩酸メクリジンを加えた処方。 EXAMPLE 6 Formulation plus meclizine hydrochloride. 塩酸メクリジン10%と低置換度ヒドロキシプロピルセルロースと結晶セルロースの配合比3:7(低置換度ヒドロキシプロピルセルロースを1とすると1:2.3となる)。 10% meclizine hydrochloride and low-substituted compounding ratio of hydroxypropylcellulose and crystalline cellulose 3: 7 (equal to 1 low-substituted hydroxypropylcellulose becomes 1: 2.3). 成 分 量 塩酸メクリジン 10.0% 結晶セルロース 62.3% 低置換度ヒドロキシプロピルセルロース 26.7% ステアリン酸マグネシウム 1.0% 上記粉末を均一に混合した後、打錠機で圧縮した。 After uniformly mixing the Ingredients Amount meclizine hydrochloride 10.0% crystalline cellulose 62.3% low-substituted hydroxypropylcellulose 26.7 percent magnesium 1.0% above stearate powder was compressed on a tablet machine. 表7 Table 7
に示したように良好な崩壊時間と打錠圧、硬度の関係を得た。 Good disintegration time and compression force as shown in, to obtain a relationship of hardness.

【0024】 [0024]

【実施例7】 塩酸メクリジンを加えた処方。 EXAMPLE 7 Formulation plus meclizine hydrochloride. 塩酸メクリジン10%と低置換度ヒドロキシプロピルセルロースと結晶セルロースの配合比1:4 成 分 量 塩酸メクリジン 10.0% 結晶セルロース 71.2% 低置換度ヒドロキシプロピルセルロース 17.8% ステアリン酸マグネシウム 1.0% 上記粉末を均一に混合した後、打錠機で圧縮した。 Mixing ratio of 10% hydrochloric acid meclizine and a low-substituted hydroxypropyl cellulose crystalline cellulose 1: 4 Ingredients Amount meclizine hydrochloride 10.0% crystalline cellulose 71.2% low-substituted hydroxypropyl cellulose 17.8% Magnesium stearate 1. after uniformly mixing 0% the powder was compressed on a tablet machine. 表8 Table 8
に示したように良好な崩壊時間と打錠圧、硬度の関係を得た。 Good disintegration time and compression force as shown in, to obtain a relationship of hardness.

【0025】 [0025]

【実施例8】 塩酸メクリジンを加えた処方。 Example 8 Formulation plus meclizine hydrochloride. 塩酸メクリジン10%と低置換度ヒドロキシプロピルセルロースと結晶セルロース配合比1:9 成分 量 塩酸メクリジン 10.0% 結晶セルロース 80.1% 低置換度ヒドロキシプロピルセルロース 8.9% ステアリン酸マグネシウム 1.0% 上記粉末を均一に混合した後、打錠機で圧縮した。 10% meclizine hydrochloride and a low-substituted hydroxypropyl cellulose crystalline cellulose mixing ratio 1: 9 Ingredients Amount meclizine hydrochloride 10.0% crystalline cellulose 80.1% low-substituted hydroxypropylcellulose 8.9% Magnesium stearate 1.0% after uniformly mixing the powder was compressed on a tablet machine. 表9 Table 9
に示したように良好な崩壊時間と打錠圧、硬度の関係を得た。 Good disintegration time and compression force as shown in, to obtain a relationship of hardness.

【0026】 [0026]

【発明の効果】本発明の速崩壊性錠剤は、小型シャーレによる崩壊試験で崩壊時間が70秒以下で、口腔内で唾液(少量の水)により数十秒程度で速やかに崩壊する錠剤を提供することを可能とする。 Effects of the Invention fast disintegrating tablet of the present invention is a disintegration time in the disintegration test according to small Petri dish below 70 seconds, provide tablets that disintegrate rapidly in several tens of seconds by the saliva (a small amount of water) in the oral cavity It makes it possible to. その結果、嚥下力の弱い老人が服用する錠剤、水の無い場面での錠剤の服用を可能にするものである。 As a result, the tablets to be taken is weak swallowing force the elderly, it is those that permit the taking of tablets in the absence of water scene.

Claims (1)

    【特許請求の範囲】 [The claims]
  1. 【請求項1】 組成が薬物、結晶セルロース、低置換度ヒドロキシプロピルセルロース、滑沢剤を混合した物からなり、低置換度ヒドロキシプロピルセルロースと結晶セルロースの配合比が低置換度ヒドロキシプロピルセルロースを1として1:2.3から1:9で配合・混合したものを圧縮成型することよりなる口腔内で崩壊性の速い錠剤。 1. A composition drug, crystalline cellulose, low-substituted hydroxypropylcellulose, consists of a mixture a lubricant, compounding ratio of the crystalline cellulose and low-substituted hydroxypropyl cellulose is low-substituted hydroxypropylcellulose 1 as 1: 2.3 to 1: fast tablet disintegration property in the oral cavity consisting of compression molding a material obtained by blending and mixing in 9.
JP26458395A 1995-09-07 1995-09-07 Tablet quickly disintegrating in oral cavity Pending JPH0971523A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP26458395A JPH0971523A (en) 1995-09-07 1995-09-07 Tablet quickly disintegrating in oral cavity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26458395A JPH0971523A (en) 1995-09-07 1995-09-07 Tablet quickly disintegrating in oral cavity

Publications (1)

Publication Number Publication Date
JPH0971523A true true JPH0971523A (en) 1997-03-18

Family

ID=17405316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP26458395A Pending JPH0971523A (en) 1995-09-07 1995-09-07 Tablet quickly disintegrating in oral cavity

Country Status (1)

Country Link
JP (1) JPH0971523A (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053798A1 (en) * 1997-05-27 1998-12-03 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
WO1998042310A3 (en) * 1997-03-22 1998-12-23 Boots Co Plc Fast release compressed tablet of flurbiprofen
JPH1143429A (en) * 1997-05-27 1999-02-16 Takeda Chem Ind Ltd Solid preparation
WO1999018936A1 (en) * 1997-10-09 1999-04-22 Ssp Co., Ltd. Quickly soluble solid preparations
FR2784895A1 (en) * 1998-10-23 2000-04-28 Gattefosse Ets Sa Tablets have the active material coated with a polyhydroxy ester lipid then bound with a hydroxy propyl cellulose ether to mask the flavor and give immediate liberation when crunched
US6559134B2 (en) 2000-03-17 2003-05-06 Shin-Etsu Chemical Co., Ltd. Solid preparation containing low-substituted hydroxypropyl cellulose and production process thereof
FR2845914A1 (en) * 2002-10-18 2004-04-23 Schwarz Pharma Lab Antiemetic tablet that disintegrates rapidly in the mouth, useful for treating nausea and vomiting, includes powdered agent with both disintegrating and binding properties
JP2005162613A (en) * 2002-06-14 2005-06-23 Nippon Boehringer Ingelheim Co Ltd Brotizolam-containing tablet
US7070805B2 (en) 1998-07-28 2006-07-04 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
EP1736144A2 (en) 1998-05-18 2006-12-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
JP2008509089A (en) * 2004-06-17 2008-03-27 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン Prepared by direct compression of memantine or neramexane, immediate release tablets suitable for drinking
WO2008120548A2 (en) 2007-03-13 2008-10-09 Dainippon Sumitomo Pharma Co., Ltd. Oral disintegrating tablet
WO2009022670A1 (en) * 2007-08-10 2009-02-19 Takeda Pharmaceutical Company Limited Quickly disintegrating tablet
JP2009196940A (en) * 2008-02-22 2009-09-03 Takada Seiyaku Kk Tablet quickly disintegrating in oral cavity and its production method
JP2010505791A (en) * 2006-10-06 2010-02-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Tablets for capecitabine children
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
JP2010053047A (en) * 2008-08-26 2010-03-11 Dainippon Sumitomo Pharma Co Ltd Irbesartan-containing pharmaceutical composition with good elution property and orally disintegrable tablet
JP4562797B1 (en) * 2009-05-29 2010-10-13 マイラン製薬株式会社 Orally disintegrating tablet of the precipitated calcium carbonate as an active ingredient
WO2012018056A1 (en) * 2010-08-03 2012-02-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 Compressed composition
JP2013173802A (en) * 2013-06-13 2013-09-05 Dainippon Sumitomo Pharma Co Ltd Irbesartan-containing pharmaceutical composition with excellent elution property and orally disintegrable tablet
JP2015110663A (en) * 2015-03-11 2015-06-18 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with excellent elution property and orally disintegrable tablet
JP2016183195A (en) * 2016-07-25 2016-10-20 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with excellent elution property and orally disintegrable tablet
JP2017141299A (en) * 2017-05-24 2017-08-17 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042310A3 (en) * 1997-03-22 1998-12-23 Boots Co Plc Fast release compressed tablet of flurbiprofen
US6299904B1 (en) 1997-05-27 2001-10-09 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
JPH1143429A (en) * 1997-05-27 1999-02-16 Takeda Chem Ind Ltd Solid preparation
US6586004B2 (en) 1997-05-27 2003-07-01 Takeda Chemical Industries, Ltd. Solid preparation
WO1998053798A1 (en) * 1997-05-27 1998-12-03 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
WO1999018936A1 (en) * 1997-10-09 1999-04-22 Ssp Co., Ltd. Quickly soluble solid preparations
US6455053B1 (en) 1997-10-09 2002-09-24 Ssp Co., Ltd. Quickly soluble solid preparations
EP1736144A2 (en) 1998-05-18 2006-12-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
US9901546B2 (en) 1998-05-18 2018-02-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
US7875292B2 (en) 1998-05-18 2011-01-25 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
US7431942B2 (en) 1998-05-18 2008-10-07 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
EP2263660A2 (en) 1998-05-18 2010-12-22 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
US7399485B1 (en) 1998-07-28 2008-07-15 Takeda Pharmaceutical Company Limited Rapidly Disintegrable solid preparation
US7070805B2 (en) 1998-07-28 2006-07-04 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
FR2784895A1 (en) * 1998-10-23 2000-04-28 Gattefosse Ets Sa Tablets have the active material coated with a polyhydroxy ester lipid then bound with a hydroxy propyl cellulose ether to mask the flavor and give immediate liberation when crunched
WO2000024385A1 (en) * 1998-10-23 2000-05-04 Gattefosse S.A. Tablet for crunching with masked taste and instant release of active principle and method for making same
US6559134B2 (en) 2000-03-17 2003-05-06 Shin-Etsu Chemical Co., Ltd. Solid preparation containing low-substituted hydroxypropyl cellulose and production process thereof
JP2005162613A (en) * 2002-06-14 2005-06-23 Nippon Boehringer Ingelheim Co Ltd Brotizolam-containing tablet
JP4605977B2 (en) * 2002-06-14 2011-01-05 日本ベーリンガーインゲルハイム株式会社 Tablets containing brotizolam
FR2845914A1 (en) * 2002-10-18 2004-04-23 Schwarz Pharma Lab Antiemetic tablet that disintegrates rapidly in the mouth, useful for treating nausea and vomiting, includes powdered agent with both disintegrating and binding properties
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
JP2008509089A (en) * 2004-06-17 2008-03-27 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン Prepared by direct compression of memantine or neramexane, immediate release tablets suitable for drinking
JP2010505791A (en) * 2006-10-06 2010-02-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Tablets for capecitabine children
US8778392B2 (en) 2007-03-13 2014-07-15 Dainippon Sumitomo Pharma Co., Ltd. Oral disintegrating tablet
WO2008120548A2 (en) 2007-03-13 2008-10-09 Dainippon Sumitomo Pharma Co., Ltd. Oral disintegrating tablet
US9980915B2 (en) 2007-03-13 2018-05-29 Sumitomo Dainippon Pharma Co., Ltd. Oral disintegrating tablet
WO2009022670A1 (en) * 2007-08-10 2009-02-19 Takeda Pharmaceutical Company Limited Quickly disintegrating tablet
JP2009196940A (en) * 2008-02-22 2009-09-03 Takada Seiyaku Kk Tablet quickly disintegrating in oral cavity and its production method
JP2010053047A (en) * 2008-08-26 2010-03-11 Dainippon Sumitomo Pharma Co Ltd Irbesartan-containing pharmaceutical composition with good elution property and orally disintegrable tablet
JP2011006377A (en) * 2009-05-29 2011-01-13 Mylan Seiyaku Ltd Orally disintegrable tablet which contains precipitated calcium carbonate as active ingredient
JP4562797B1 (en) * 2009-05-29 2010-10-13 マイラン製薬株式会社 Orally disintegrating tablet of the precipitated calcium carbonate as an active ingredient
WO2010137716A1 (en) * 2009-05-29 2010-12-02 マイラン製薬株式会社 Orally disintegrating tablet which contains precipitated calcium carbonate as active ingredient
WO2012018056A1 (en) * 2010-08-03 2012-02-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 Compressed composition
JPWO2012018056A1 (en) * 2010-08-03 2013-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 Compression composition
JP2013173802A (en) * 2013-06-13 2013-09-05 Dainippon Sumitomo Pharma Co Ltd Irbesartan-containing pharmaceutical composition with excellent elution property and orally disintegrable tablet
JP2015110663A (en) * 2015-03-11 2015-06-18 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with excellent elution property and orally disintegrable tablet
JP2016183195A (en) * 2016-07-25 2016-10-20 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with excellent elution property and orally disintegrable tablet
JP2017141299A (en) * 2017-05-24 2017-08-17 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet

Similar Documents

Publication Publication Date Title
US5451409A (en) Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5955107A (en) Pharmaceutical suspension tablet compositions
US4834985A (en) Controlled release pharmaceutical composition
US6365182B1 (en) Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet
US4059686A (en) Pharmaceutical preparation for oral cavity administration
US20010010825A1 (en) Rapidly disintegrable solid preparation
US6500456B1 (en) Compressed nitroglycerin tablet and its method of manufacture
US20020076437A1 (en) Flashmelt oral dosage formulation
US20020122823A1 (en) Soft tablet containing dextrose monohydrate
US20050019398A1 (en) Flashmelt oral dosage formulation
US5211958A (en) Pharmaceutical composition and process for its preparation
US6673369B2 (en) Controlled release formulation
US20050169989A1 (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
US5415871A (en) Therapeutic agents
US6740339B1 (en) Quickly disintegrating solid preparations
WO1999015155A1 (en) Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
US6875446B2 (en) Method for prophylaxis and/or treatment of thromboembolism
US6238695B1 (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
EP1681048A1 (en) Orally disintegrating composition of olanzapine or donepezil
US5958453A (en) Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
WO1999044580A1 (en) Fast disintegrating tablets
WO2010103039A1 (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US6696085B2 (en) Use of an acrylic type polymer as disintegrating agent
WO1987000044A1 (en) Therapeutic formulations with bimodal release characteristics
US6692764B2 (en) Wet granulation formulation for bisphosphonic acids

Legal Events

Date Code Title Description
A02 Decision of refusal

Effective date: 20040210

Free format text: JAPANESE INTERMEDIATE CODE: A02